Novartis Ag (NVS) Accounts Payables (2009 - 2026)

Novartis Ag has disclosed Accounts Payables across 18 years of filings, most recently posting $4.3 billion for Q2 2026.

• In Q2 2026, Accounts Payables fell 5.5% year-over-year to $4.3 billion; the TTM figure through Jun 2026 stood at $4.3 billion (down 5.5% YoY), while the FY2025 annual figure was $4.5 billion, down 2.54% from the prior year.
• Accounts Payables came in at $4.3 billion for Q2 2026 at Novartis Ag, down from $4.3 billion in the prior quarter.
• In the past five years, Accounts Payables ranged from a high of $5.4 billion in Q1 2023 to a low of -$67.0 million in Q1 2022.
• Average Accounts Payables over 5 years is $4.3 billion, with a median of $4.5 billion recorded in 2025.
• Year-over-year, Accounts Payables tumbled 2133.33% in 2022 and soared 8198.51% in 2023.
• Over 5 years, Accounts Payables stood at $5.1 billion in 2022, then declined by 4.28% to $4.9 billion in 2023, then fell by 7.19% to $4.6 billion in 2024, then dropped by 2.54% to $4.5 billion in 2025, then retreated by 4.44% to $4.3 billion in 2026.
• Per Business Quant data, the three most recent Accounts Payables figures were $4.3 billion in Q2 2026, $4.3 billion in Q1 2026, and $4.5 billion in Q4 2025.